Journal: Reports of Biochemistry & Molecular Biology

Article Title: The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma

doi: 10.52547/rbmb.12.1.83

Figure Lengend Snippet: Immunohistochemical staining for p16 protein in invasive ductal breast tumors. A. p16 negative, B. p16 low positive, C. High-positive.

Article Snippet: Parameters P16 Protein Expression Level P-value(Chi-Square) Negative (n = 29) Low-Positive (n = 44) High-Positive (n = 27) ER receptor Positive 22 (75.9%) 41 (93.2%) 17 (63%) 0.007* Negative 7 (24.1%) 3 (6.8%) 10 (37%) PR receptor Positive 14 (48.3%) 33 (75%) 16 (59.3%) 0.061 Negative 15 (51.7%) 11 (25%) 11 (40.7%) HER2 Positive 4 (13.8%) 15 (34.1%) 11 (40.7%) 0.065 Negative 25 (86.2%) 29 (65.9%) 16 (59.3%) Ki67 Positive (> 14%) 7 (24.1%) 16 (36.4%) 5 (18.5%) 0.229 Negative (≤ 14%) 22 (75.9%) 28 (63.6%) 22 (81.5%) Cancer Grade I 2 (6.9%) 2 (4.5%) 4 (14.8%) 0.252 II 20 (69%) 37 (84.1%) 17 (6%) III 7 (24.1%) 5 (11.4%) 6 (22.2%) Tumor Size ≤ 20 mm 11 (37.9%) 18 (40.9%) 13 (48.1%) 0.754 21-50 mm 18 (62.1%) 25 (56.8%) 14 (51.9%) > 50 mm 0 (0%) 1 (2.3%) 0 (0%) Cancer Type Luminal A 7 (29.16%) 13 (54.16%) 4 (16.66%) 0.144 Luminal B 15 (26.31%) 28 (49.12%) 14 (24.56%) HER2 positive 2 (28.57%) 1 (14.28%) 4 (57.14%) Triple Negative 5 (41.66%) 2 (16.66%) 5 (41.66%) Age ≤ 40 years 7 (24.1%) 11 (25%) 10 (37%) 0.471 > 40 yea 22 (75.9%) 33 (75%) 17 (63%) Family History Yes 5 (17.2%) 11 (25%) 5 (18.5%) 0.68 No 24 (82.8%) 33 (75%) 22 (81.5%) Open in a separate window The data are shown as mean ± SD.

Techniques: Immunohistochemical staining, Staining

Journal: Reports of Biochemistry & Molecular Biology

Article Title: The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma

doi: 10.52547/rbmb.12.1.83

Figure Lengend Snippet: Correlation between clinicopathological characteristics and p16 protein expression in women with invasive ductal breast carcinoma.

Article Snippet: Parameters P16 Protein Expression Level P-value(Chi-Square) Negative (n = 29) Low-Positive (n = 44) High-Positive (n = 27) ER receptor Positive 22 (75.9%) 41 (93.2%) 17 (63%) 0.007* Negative 7 (24.1%) 3 (6.8%) 10 (37%) PR receptor Positive 14 (48.3%) 33 (75%) 16 (59.3%) 0.061 Negative 15 (51.7%) 11 (25%) 11 (40.7%) HER2 Positive 4 (13.8%) 15 (34.1%) 11 (40.7%) 0.065 Negative 25 (86.2%) 29 (65.9%) 16 (59.3%) Ki67 Positive (> 14%) 7 (24.1%) 16 (36.4%) 5 (18.5%) 0.229 Negative (≤ 14%) 22 (75.9%) 28 (63.6%) 22 (81.5%) Cancer Grade I 2 (6.9%) 2 (4.5%) 4 (14.8%) 0.252 II 20 (69%) 37 (84.1%) 17 (6%) III 7 (24.1%) 5 (11.4%) 6 (22.2%) Tumor Size ≤ 20 mm 11 (37.9%) 18 (40.9%) 13 (48.1%) 0.754 21-50 mm 18 (62.1%) 25 (56.8%) 14 (51.9%) > 50 mm 0 (0%) 1 (2.3%) 0 (0%) Cancer Type Luminal A 7 (29.16%) 13 (54.16%) 4 (16.66%) 0.144 Luminal B 15 (26.31%) 28 (49.12%) 14 (24.56%) HER2 positive 2 (28.57%) 1 (14.28%) 4 (57.14%) Triple Negative 5 (41.66%) 2 (16.66%) 5 (41.66%) Age ≤ 40 years 7 (24.1%) 11 (25%) 10 (37%) 0.471 > 40 yea 22 (75.9%) 33 (75%) 17 (63%) Family History Yes 5 (17.2%) 11 (25%) 5 (18.5%) 0.68 No 24 (82.8%) 33 (75%) 22 (81.5%) Open in a separate window The data are shown as mean ± SD.

Techniques: Expressing

Journal: Reports of Biochemistry & Molecular Biology

Article Title: The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma

doi: 10.52547/rbmb.12.1.83

Figure Lengend Snippet: Correlation of p16 expression with tumor grade and age of patients with invasive ductal breast carcinoma. The data are shown as mean ± SD.

Article Snippet: Parameters P16 Protein Expression Level P-value(Chi-Square) Negative (n = 29) Low-Positive (n = 44) High-Positive (n = 27) ER receptor Positive 22 (75.9%) 41 (93.2%) 17 (63%) 0.007* Negative 7 (24.1%) 3 (6.8%) 10 (37%) PR receptor Positive 14 (48.3%) 33 (75%) 16 (59.3%) 0.061 Negative 15 (51.7%) 11 (25%) 11 (40.7%) HER2 Positive 4 (13.8%) 15 (34.1%) 11 (40.7%) 0.065 Negative 25 (86.2%) 29 (65.9%) 16 (59.3%) Ki67 Positive (> 14%) 7 (24.1%) 16 (36.4%) 5 (18.5%) 0.229 Negative (≤ 14%) 22 (75.9%) 28 (63.6%) 22 (81.5%) Cancer Grade I 2 (6.9%) 2 (4.5%) 4 (14.8%) 0.252 II 20 (69%) 37 (84.1%) 17 (6%) III 7 (24.1%) 5 (11.4%) 6 (22.2%) Tumor Size ≤ 20 mm 11 (37.9%) 18 (40.9%) 13 (48.1%) 0.754 21-50 mm 18 (62.1%) 25 (56.8%) 14 (51.9%) > 50 mm 0 (0%) 1 (2.3%) 0 (0%) Cancer Type Luminal A 7 (29.16%) 13 (54.16%) 4 (16.66%) 0.144 Luminal B 15 (26.31%) 28 (49.12%) 14 (24.56%) HER2 positive 2 (28.57%) 1 (14.28%) 4 (57.14%) Triple Negative 5 (41.66%) 2 (16.66%) 5 (41.66%) Age ≤ 40 years 7 (24.1%) 11 (25%) 10 (37%) 0.471 > 40 yea 22 (75.9%) 33 (75%) 17 (63%) Family History Yes 5 (17.2%) 11 (25%) 5 (18.5%) 0.68 No 24 (82.8%) 33 (75%) 22 (81.5%) Open in a separate window The data are shown as mean ± SD.

Techniques: Expressing

Journal: Breast Cancer Research : BCR

Article Title: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

doi: 10.1186/bcr3690

Figure Lengend Snippet: The relationship between biomarker levels and whether a pathologic complete response (pCR) was achieved, adjusted for estrogen receptor status (all arms pooled)

Article Snippet: Targos Molecular Pathology GmbH, Kassel, Germany conducted analysis of: mRNA expression levels of HER2 , HER3, EGFR, amphiregulin, and betacellulin ; protein expression levels of HER3, EGFR, IGF-1R, and PTEN and of c-myc and TOP2A gene amplification.

Techniques: Biomarker Discovery, Membrane, Mutagenesis

Journal: Breast Cancer Research : BCR

Article Title: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

doi: 10.1186/bcr3690

Figure Lengend Snippet: Comparison of baseline levels of biomarkers derived from tissue samples with the levels detected at surgery. (A) PTEN nuc, (B) HER2-CR, ( C ) EGFR-CR, (D) HER2-mem. (In the box plot, the horizontal line represents the median value, the diamond represents the mean, the upper and lower bounds of the box represent the 75th and 25th quartiles, respectively, and whiskers represent 95% confidence limits). CR, concentration ratio; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; mem, membrane; nuc, nuclear; PTEN, phosphatase and tensin homolog.

Article Snippet: Targos Molecular Pathology GmbH, Kassel, Germany conducted analysis of: mRNA expression levels of HER2 , HER3, EGFR, amphiregulin, and betacellulin ; protein expression levels of HER3, EGFR, IGF-1R, and PTEN and of c-myc and TOP2A gene amplification.

Techniques: Comparison, Derivative Assay, Concentration Assay, Membrane

Journal: Biomolecules

Article Title: Differential MicroRNA Expression Involved in Endometrial Receptivity of Goats

doi: 10.3390/biom11030472

Figure Lengend Snippet: Chi-miR-483 targets the 3′-untranslated region (UTR) of deltex E3 ubiquitin ligase 3L (DTX3L). ( A ) The predicted binding site of chi-miR-483 in the 3′UTR of DTX3L according to bioinformatics analysis. ( B ) Design of the luciferase reporter. WT, the wildtype sequence of DTX3L-3′UTR contains the chi-miR-483 binding site; Mut, the sequence of DTX3L-3′UTR with a mutation in the chi-miR-483 binding site. ( C ) 293T cells were co-transfected with wildtype (WT) or mutant (Mut) luciferase reports of DTX3L 3′UTR with chi-miR-483 mimics or negative control (NC) mimics. The luciferase reporter assay demonstrated that chi-miR-483 significantly decreased the luciferase activity of DTX3L WT in 293T cells. Data are shown as the mean ± SEM values ( n = 3, ** p < 0.01, Student’s t -test).

Article Snippet: Differences in wildtype (WT) or mutant (Mut) DTX3L 3′UTR luciferase reports and the expression level of DTX3L protein under two conditions were compared using Student’s t -test (GraphPad Prism version 8.0, San Diego, CA, USA).

Techniques: Ubiquitin Proteomics, Binding Assay, Luciferase, Sequencing, Mutagenesis, Transfection, Negative Control, Reporter Assay, Activity Assay

Journal: Biomolecules

Article Title: Differential MicroRNA Expression Involved in Endometrial Receptivity of Goats

doi: 10.3390/biom11030472

Figure Lengend Snippet: Immunohistochemical analysis of DTX3L in the C16 and P16 uterus. ( A ) Images stained with DTX3L antibodies. The positive signal of DTX3L was distinctly detected in the uterine luminal epithelium or glandular epithelium in P16. The section stained with nonrelevant immunoglobulin G served as the negative control (NC). ( B ) Quantitative analysis of DTX3L by measuring the average integrated optical density (IOD) in the endometrium. Asterisks indicate significant differences (mean ± SEM) between C16 and P16 (*** p < 0.001); the p -value was determined by Student’s t -test. Legend: LE, endometrial luminal epithelium; GE, glandular epithelium. Scale bar = 100 μm.

Article Snippet: Differences in wildtype (WT) or mutant (Mut) DTX3L 3′UTR luciferase reports and the expression level of DTX3L protein under two conditions were compared using Student’s t -test (GraphPad Prism version 8.0, San Diego, CA, USA).

Techniques: Immunohistochemical staining, Staining, Negative Control